Medroxyprogesterone — Discount Pricing

Other medications in Hormones

• Norethindrone
• Octreotide
• Progesterone
• Tamoxifen
• Testosterone Cypionate
• Testosterone Gel
• Anastrozole
• Cabergoline

What Medroxyprogesterone is approved for (FDA label)

Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.

Source: Read the full FDA label on DailyMed. Label effective date: October 9, 2022.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Medroxyprogesterone (FDA label)

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. ( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable Dementia . ) The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. ( See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders . ) The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo.

Source: FDA prescribing information (DailyMed). Set ID: 1403a9a9-c04a-432f-8819-4850f779312e. SPL document ID: eaa58b56-e846-aab7-e053-2995a90a49c2. Label effective date: October 9, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Medroxyprogesterone (FDA label)

See BOXED WARNINGS , WARNINGS , and PRECAUTIONS . Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 1403a9a9-c04a-432f-8819-4850f779312e. SPL document ID: eaa58b56-e846-aab7-e053-2995a90a49c2. Label effective date: October 9, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Medroxyprogesterone (FDA label)

Medroxyprogesterone acetate is contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding. Known, suspected, or history of breast cancer. Known or suspected estrogen- or progesterone-dependent neoplasia. Active DVT, PE, or a history of these conditions Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions. Known anaphylactic reaction or angioedema to medroxyprogesterone acetate. Known liver impairment or disease. Known or suspected pregnancy.

Source: FDA prescribing information (DailyMed). Set ID: 1403a9a9-c04a-432f-8819-4850f779312e. SPL document ID: eaa58b56-e846-aab7-e053-2995a90a49c2. Label effective date: October 9, 2022. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.